| Autor: |
Camera M; Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.; Centro Cardiologico Monzino IRCCS, Milan, Italy., Canzano P; Centro Cardiologico Monzino IRCCS, Milan, Italy., Brambilla M; Centro Cardiologico Monzino IRCCS, Milan, Italy., Rovati GE; Department of Pharmaceutical Sciences, University of Milan, Milan, Italy. |
| Jazyk: |
angličtina |
| Zdroj: |
Frontiers in pharmacology [Front Pharmacol] 2022 Feb 08; Vol. 13, pp. 784214. Date of Electronic Publication: 2022 Feb 08 (Print Publication: 2022). |
| DOI: |
10.3389/fphar.2022.784214 |
| Abstrakt: |
Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely LTC 4 , LTD 4 , and LTE 4 are involved in many of the principal features of asthma, while more recently they have also been implicated in cardiovascular diseases. COVID-19 is characterized by an overwhelming state of inflammation, sometimes resulting in an acute respiratory distress syndrome. Furthermore, severe COVID-19 patients present an endothelial cell damage characterized by a hyperinflammatory/procoagulant state and a widespread thrombotic disease. Leukotriene receptor antagonists, such as montelukast, have long been proven to have an efficacy in asthma, while more recently they have been suggested to have a protective role also in cardiovascular diseases. As elevated levels of LTE 4 have been detected in bronchoalveolar lavage of COVID-19 patients, and montelukast, in addition to its anti-inflammatory properties, has been suggested to have a protective role in cardiovascular diseases, we decided to investigate whether this drug could also affect the platelet activation characteristic of COVID-19 syndrome. In this contribution, we demonstrate that montelukast inhibits platelet activation induced by plasma from COVID-19 patients by preventing the surface expression of tissue factor (TF) and P-selectin, reducing the formation of circulating monocyte- and granulocyte-platelet aggregates, and, finally, in completely inhibiting the release of TF pos -circulating microvesicles. These data suggest the repurposing of montelukast as a possible auxiliary treatment for COVID-19 syndrome.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Camera, Canzano, Brambilla and Rovati.) |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
